Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP-104GI in Adults With Eosinophilic Esophagitis (RESOLVE)
NCT05608681Phase 2Recruiting
- Sponsor
- Eupraxia Pharmaceuticals Inc.
- Start
- Mar 2023
- Primary completion
- Dec 2026
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of EP-104GI in eosinophilic esophagitis (EoE), sponsored by Eupraxia Pharmaceuticals Inc.. Started Mar 2023; status: recruiting.
02
Drugs
EP-104GI
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT05608681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05608681.